Paula Rodríguez Otero, MD, PhD, on Demonstrating Ide-cel's PFS Superiority in Triple-Class-Exposed R/R Multiple Myeloma
The hematologist at the University of Navarra discussed updated data from the phase KarMMa-3 trial.